Bimiralisib is under clinical development by Torqur and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase II drugs for Cutaneous T-Cell Lymphoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bimiralisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bimiralisib (PQR-309) is under development for the treatment of diffuse large B-cell lymphoma and cutaneous T cell lymphoma. The therapeutic candidate is administered through oral and topical route as gel. PQR-309 targets all isoforms of PI3K and mTOR. It is developed using high-throughput and low-throughput-high-output discovery and validation platforms.
The drug candidate was also under development for the treatment of metastatic HER2 negative and triple-negative breast cancer, solid tumors, relapsed/refractory chronic lymphoid leukemia and primary CNS lymphoma, inflammation, plaque psoriasis, glioblastoma multiforme, recurrent head and neck squamous cell carcinoma, eye, central nervous system disorders.
Torqur, (Torqur), a subsidiary of Swiss Rockets, develops novel anticancer therapeutics targeting the metabolic PI3K/mTOR intracellular signalling pathway. Torqur is headquartered in Basel, Switzerland.
For a complete picture of Bimiralisib’s drug-specific PTSR and LoA scores, buy the report here.